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Background: To estimate the amount of regret and weights of harm by omission and commission during
therapeutic decisions for smear-negative pulmonary Tuberculosis.
Methods: An interviewer-administered survey was done among young physicians in India, Pakistan and Bangladesh
with a previously used questionnaire. The physicians were asked to estimate probabilities of morbidity and mortality
related with disease and treatment and intuitive weights of omission and commission for treatment of suspected
pulmonary Tuberculosis. A comparison with weights based on literature data was made.
Results: A total of 242 physicians completed the interview. Their mean age was 28 years, 158 (65.3%) were males.
Median probability (%) of mortality and morbidity of disease was estimated at 65% (inter quartile range [IQR] 50-75)
and 20% (IQR 8-30) respectively. Median probability of morbidity and mortality in case of occurrence of side effects
was 15% (IQR 10-30) and 8% (IQR 5-20) respectively. Probability of absolute treatment mortality was 0.7% which
was nearly eight times higher than 0.09% reported in the literature data. The omission vs. commission harm ratios
based on intuitive weights, weights calculated with literature data, weights calculated with intuitive estimates of
determinants adjusted without and with regret were 3.0 (1.4-5.0), 16 (11-26), 33 (11-98) and 48 (11-132) respectively.
Thresholds based on pure regret and hybrid model (clinicians’ intuitive estimates and regret) were 25 (16.7-41.7),
and 2(0.75-7.5) respectively but utility-based thresholds for clinicians’ estimates and literature data were 2.9 (1-8.3)
and 5.9 (3.7-7.7) respectively.
Conclusion: Intuitive weight of harm related to false-negatives was estimated higher than that to false-positives.
The mortality related to treatment was eightfold overestimated. Adjusting expected utility thresholds for subjective
regret had little effect.
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Pulmonary Tuberculosis (PTB) is a major cause of mor-
bidity and mortality worldwide, particularly in low-and-
middle-income countries (LMICs) [1,2]. Early and optimal
treatment of both smear-negative and smear-positive ca-
ses is the only effective strategy available for TB control
[3]. Although an effective treatment is available, diagnostic
methods such as sputum smear and sputum culture are
not sensitive enough and facilities for culture are scarcely
available in LMICs [3]. Physicians often face a dilemma
when sputum smear and/or culture are negative in a sus-
pected PTB patient, since several national guidelines rec-
ommend bacteriological confirmation before initiating the
anti-TB treatment. However, the clinicians at referral
(tertiary care) hospitals argue that most patients having
clinical features of PTB but negative bacteriological tests
deserve an adequate treatment [4]. Moreover, many refer-
ral hospitals are confronted with relatively more smear-
negative PTB (SNPTB) cases than the lower level health
facilities [5]. Clinicians are still reluctant to initiate treat-
ment for SNPTB suspects due to non-availability of newer
TB diagnostic tools [3,4]. Since the sensitivity of sputum
culture is not higher than 60%, far too many false negative
cases would be left untreated, if bacteriological proof were
compulsory for treatment [4,6,7].
Pauker and Kassirer have recommended a decision
threshold approach to solve conflicting issues such as
treatment of SNPTB. They have defined the ‘decision
threshold’ as a minimum required probability of the dis-
ease for allowing initiation of treatment. This approach
is based on a compromise between factors associated
with the treatment itself and those if the disease is left
untreated [8]. ‘Threshold’ is defined as the (post-workup)
probability of the disease at which the risk and cost of a
diseased person left untreated equals the risk and cost of
treatment of both the diseased and non-diseased. The
probabilities and values of harm and benefit of a treatment
must be taken into account to formally estimate the re-
quired level of certainty to justify a treatment [9]. This
concept though has been applied to other medical condi-
tions; so far only two studies have been published about
SNPTB [5,10]. The first study of Basinga et al. from
Rwanda has reported that physicians’ intuitive treatment
threshold for SNPTB was 52.5% but a threshold based
on literature data was only 2.8% [5].The second study,
by Moreira et al. from four countries (Nepal, Ecuador,
Laos and Rwanda) has reported that physicians’ intuitive
weights (on a 10-point Likert scale) of harm by commis-
sion (treating a person who indeed is not diseased) and
omission (not treating a person who is diseased) were 4.5
versus 10 respectively in therapeutic decision making for
SNPTB [10].
Zikmund-Fisher et al. argue that the decisions related
to life-and-death situations should consider emotionalfactors of both decision makers and patients who are af-
fected by these decisions [11]. Hence these subjective
factors not directly related to the disease and its treat-
ment should be taken into account while making thera-
peutic decisions.
Generally patients’ perspectives are emphasised, but all
important clinicians’ perspectives of therapeutic decisions
are rarely studied. Previous studies on SNPTB (clinicians’
perspective) and parental perspectives for child vaccin-
ation against pertussis and influenza have highlighted that
feelings of regret from provoked harm of medical in-
terventions do affect the decision making [5,10,12,13]. A
detailed analysis of the subjective (emotional) factors is
useful in guiding clinicians in estimation of sound decision
thresholds. Studies about weights of harm by omission
and commission are important since correctness of thera-
peutic decisions has implications on patient care as well as
on population health in LMICs and worldwide [10,14].
Regret in decision making can be investigated in diffe-
rent ways. Gross estimation of subjective regret for a com-
mission or omission error can be given on a visual analog
scale [15]. Expected harm of commission vs. omission can
be calculated based on estimations of clinicians or litera-
ture data of mortality and morbidity related to disease and
treatment via expected utility methodology [8]. Gross esti-
mation (‘holistic approach’) might correspond to the ‘thin-
king fast’ (system I) and the expected utility method to the
‘thinking slow’ (system II) proposed by Kahneman [16].
Both are combined in the dual processing model proposed
by Djulbegovic et al. [17]. In this model the authors add
regret, which they limit to the system I, to the expected
utility based analytical reasoning in an additive way. Regret
can also be applied, not added to probabilities estimated by
clinicians or found in the literature (hybrid model) [5,18].
Earlier research showed that the results of gross estimation
might be very different from harm computed from clini-
cians’ estimations of mortality and morbidity, even after
adjusting these estimations for omission/commission re-
gret [5]. In this study, we apply the ‘hybrid model’.
India, Pakistan and Bangladesh are among the 22 high-
burden TB countries, but so far no study has been done
about physicians’ intuitive weights of harm during thera-
peutic decisions for SNPTB. We estimated the ‘weights of
regret’ due to death resulting from omission or commis-
sion (as compared to natural death) in a suspected SNPTB
patient. In parallel, to have an objective standard of com-
parison, we substituted literature probabilities for physi-
cians’ intuitive estimates to calculate the weights of false
positives and false negatives.
Method
Study design
A cross-sectional, interviewer-administered questionnaire
survey.
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Medical professionals from Bangladesh, India and Pakistan
were selected for this survey. The participants had varying
lengths of clinical experience and were working at dif-
ferent settings such as primary care, teaching hospitals
attached to medical schools and tertiary care hospitals.
The participants had not received any formal training in
medical decision making. The main indicators for burden
of TB and HIV, and indicators of TB control program for
these countries are shown in Table 1 [19].
Sampling and sample size
From each country, we recruited medical professionals
affiliated to a medical school who are likely to care for sus-
pected TB patients in their clinical practice and physicians
working at primary health care centers (in Bangladesh
only). We did not use any formal sample size calculation.
Questionnaire
The conceptual framework and study instrument we
used was based on the study by Moreira et al. [10]. Only
a few minor modifications were made. An English version
of the questionnaire was administered to the participants
during an interview conducted by the collaborating re-
searchers from three countries. The questionnaire (see
Additional file 1) contained information about demo-
graphics, years of experience, area of specialisation and
case scenarios. The interviewers explained the case sce-
narios to each participant. The case scenarios explored
the information about two main themes: i) perceived
probabilities related to the disease and the treatment;
and ii) intuitive values regarding the harm caused by
the wrong decisions. In each of the case scenarios 1-5,
the interviewers asked the participants to guess (perceived
probabilities ranging from 0%-100%) about an estimated
mortality and morbidity of untreated PTB and about theTable 1 Characteristics of countries
Characteristics
World Bank classification based on income
Total population (thousands)
TB mortality per 100,000 population-year (excludes HIV + TB)
TB prevalence 100,000 population-year (includes HIV + TB)
TB incidence 100,000 population-year (includes HIV + TB)
HIV prevalence in incident TB cases (%)
Incidence 100,000 population-year (HIV + TB)
Estimated% of new TB cases with MDR-TB
Estimated% of previously treated TB cases with MDR-TB
Percent new pulmonary cases smear- positive
Estimates of the case detection rate of new & relapse cases
Treatment success for all new cases (%) in 2010
Source: World Health Organization. Global tuberculosis report 2012.risk of morbidity and mortality caused by anti-TB treat-
ment. In case scenario five, the participants were asked
about the weights of regret arising from decisions namely;
1) forgoing treatment in a false negative case, 2) treating a
false positive case, and 3) death related to a given decision
despite this was based on optimal grounds. Weight of re-
gret due to wrong decisions was estimated on a 10-point
Likert scale while the weights of regret arising from death
related to decisions was rated in comparison to natural
death (death without any medical intervention) for which
a weight of ‘1’ was assigned (refer to Additional file 1 for
details). The cost of treatment was not estimated because
anti-TB treatment is given free-of-cost for the patients
under Directly Observed Treatment, Short course (DOTS)
strategy in all three countries.Data collection
Between April and September, 2012 the research col-
laborators from each country interviewed the physi-
cians. Ethical approval was obtained from research
ethics committee of University Tunku Abdul Rahman,
Selangor, Malaysia. Collaborators from India, Pakistan
and Bangladesh, also obtained approval from ethics
committees of the medical schools they were affiliated
to. The potential participants were briefed about the re-
search and informed consent was sought. Consenting
physicians were interviewed face-to-face using the ques-
tionnaire. The researchers explained the scenarios to
the participants and asked them to estimate the prob-
abilities and weights of regret.Variables
Using the information about estimated probabilities and
weights of harm some indicators were constructed ac-
cording to methods used by Moreira et al. [10].India Pakistan Bangladesh
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WFN ¼ dis mortþ dis morb  w dis morbð Þ  regr pr harm om
Where,
dis_mort =Mortality related with an untreated disease.
dis_ morb =Morbidity related with an untreated disease.
w_dis _morb =Weight of morbidity related with an un-
treated disease, which is the complement of the health sta-
tus of a person affected by the disease compared with a
healthy person of the same age (details about the question
in the Additional file 1).
regr_ pr_ harm_ om = Regret for harm provoked by er-
roneous omission of the treatment.
Weight of a false positive (WFP)
WFP ¼ tr mort þ tr morb  w tr morbð Þ  regr pr þ harm tr
Where,
tr_mort =Mortality due to a severe side effect of the
treatment.
tr_morb =Morbidity due to severe side effects of the
treatment.
w_ tr _morb =Weight of morbidity due to severe side
effects of the treatment.
regr_ pr_ harm_ tr = Regret for harm provoked by the
treatment (death in a non-diseased).
‘Calculated’ WFN and WFP were also computed with-
out regret, and further by substituting estimated prob-
abilities for literature data on mortality and morbidity
(Table 2) into the equations given above. Further the ra-
tios between weight of false negative (WFN) and weight
of false positive (WFP) were calculated.
The effect of data and estimations was incorporated fi-
nally in four thresholds: the first based on gross clini-
cians’ estimation of the weight of harm by commission
vs. harm by omission; the second based on literature
data [20-38]; a third based on estimation of probabilities
of morbidity and mortality by the clinicians; and a last
based on these estimations plus regret conditional on
these probabilities, estimated by the clinicians.Table 2 Data from the literature on probabilities of
mortality and morbidity related to the disease (TB) and
treatment of tuberculosis




Disease mortality 55 49-66 3 [20]
Disease morbidity 19 18-19 3 [21,22]
Treatment
morbidity
5.8 1.8-12.5 12 [23-33]
Treatment mortality 0.09 0.02-0.4 6 [24,34-38]Data analysis
Data entry and analysis (see Additional file 2) was per-
formed with SPSS (Statistical Package for Social Sciences)
version 14.0 for windows. A comparison of estimated pro-
babilities and weights was made between the countries
and according to gender. The differences were tested for
statistical significance using the Kruskal-Wallis test. A
comparison between ratios of WFN/WFP calculated by
four different approaches was made and the difference
was tested for statistical significance using the Friedman
test. Spearman’s rank correlation coefficient was used to
test the relationship of ratios of WFN/WFP (both intuitive
and calculated weights) with years of clinical experience.
For all statistical tests a p-value of less than 0.05 was con-
sidered as significant.
Results
A total of 242 clinicians were interviewed from three coun-
tries, namely, India (77), Pakistan (84) and Bangladesh (81).
Overall median age of the participants was 28 years,
female-to-male ratio 1/1.9. Median years of experience was
3 and 98 (40.5%) were specialist consultants (46 in internal
medicine, the others in other specialties) (Table 3). Ten
participants, six from India and four from Bangladesh were
excluded from the analysis since they gave incomplete re-
sponses for either the probabilities or the weights of harm.
Estimated probabilities (%)
Overall median probabilities for mortality and morbidity
from the disease were 65% (IQR 50-75) and 20 (IQR 8-30)
and were significantly different among three countries.
Overall median probability for occurrence of side effects,
morbidity and mortality in case side effects occur was 10%
(IQR 5-20), 15% (IQR 10-30) and 8% (IQR 5-20) respec-
tively and were also significantly different among three
countries (Table 4). Female participants estimated signifi-
cantly higher probabilities for morbidity and mortality
from the side effects (p = 0.009 and p = 0.031 respectively).
Estimated weights (relative to perfect health) of
morbidity related with disease and treatment
Overall median estimated weights (%) of morbidity rela-
ted to disease and treatment (as a complement of health
status of a person who is diseased as compared to a
healthy person; case scenarios 4 & 5 in the questionnaire)
were 25% (IQR 15-40) and 60% (IQR 40-80) respectively
and the weights were significantly different among three
countries. The median weights estimated for regrets of
death due to omission, provoked but unjustified death and
provoked but justified death were 4 (IQR 3-5), 3 (IQR 2-4)
and 1 (IQR 1-2) respectively and the difference between
three types of estimated weights was statistically signifi-
cant. The differences in three types of regret between the
countries were also statistically significant (Table 5).
Table 3 Demographic characteristics of the respondents in India, Pakistan and Bangladesh
India (n = 77) Pakistan (n = 84) Bangladesh (n = 81) All countries (n = 242)
Age in years (median and IQR) 30 (26, 39) 24 (23, 26) 34 (29, 40) 28.0 (24, 36.3)
Experience in years (median and IQR) 3 (1.5, 8) 1 (0.5, 2) 9.0 (4.5, 14) 3.0 (0.8,9)
Sex (number and %)
Male 46 (59.7) 47(56) 65 (80.2) 158 (65.3)
Female 31 (40.3) 37 (44) 16 (19.8) 84 (34.7)
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Overall medians for intuitive WFN and WFP were 9
(IQR 7-10), and 3 (IQR 1-6) respectively. The median
intuitive WFP was significantly different among three
countries whereas median intuitive WFN was similar in
three countries. In Bangladesh, seven participants had
estimated intuitive WFP as zero and six participants had
estimated intuitive WFN as zero.
Overall median calculated WFN and WFP based on
literature data, without regret were 59 (57-62) and 3.5
(2.4-4.7). Overall median calculated WFN and WFP based
on intuitive estimates without regret were 71 (57-81) and
1.7 (0.6-5.8). Overall median calculated WFN and WFP
based on intuitive estimates adjusted for regret were 252
(148-336) and 5 (1.83-17.29) (Table 6).WFN/WFP Ratios and thresholds
The omission vs. commission harm ratio based on in-
tuitive weights given on a 10-point Likert scale was 3.0
(1.4-5.0), corresponding to a threshold of 25%. This ratio
based on expected utility theory with weights calculated
with literature data was 16 (11-26), with a threshold of
5.9. The same with estimations by the clinicians instead
of literature data gave a ratio of 33 (11-98) and a thres-
hold of 2.9%. The hybrid approach, where regret for an
unjustified death was applied to mortality estimations byTable 4 Estimated probabilities (%) of morbidity and mortalit
SNPTB (median and inter quartile range)
India (n =
1 Mortality from untreated SNPTB* 70 (65-75)
2 Morbidity from untreated SNPTB¶ 5 (5-10)
3 Probability of side effects occurring if SNPTB is treated¶ 6 (3-9)
4 Conditional probability of death due to side effects if they
occur when SNPTB is treated¶
5 (3-5)
5 Conditional probability of morbidity as a result of side effects
when SNPTB is treated¶
10 (7-15)
6 Absolute probability of mortality arising from side effects of
anti-TB treatment¶×
0.25 (0.11-




× Calculated as row 3 × row 4.
π calculated as row 3 × row 5.
*p < 0.01.the clinicians gave a ratio of 48 (11-132), with a thresh-
old of 2 (Table 7 and Figure 1).
Years of experience were negatively correlated with both
clinicians’ estimated and calculated WFN and WFP.
Spearman’s correlation coefficients ranged from -0.046
to -0.229 (details not shown).
Discussion
Results
The participants in three countries estimated the pro-
babilities of morbidity and mortality from disease quite
accurately since the estimated probabilities were com-
parable to the literature data. The mortality of treatment
was over estimated by eight times. The intuitive estima-
ted weight of regret about omission (false negative) was
three times higher than the weight of regret about com-
mission (false positive). This is in line with earlier re-
search [14]. Even when WFN and WFP were calculated
by other methods i.e. based on intuitive estimates of mor-
bidity, mortality and literature probabilities, the WFN was
much higher than the WFP in three countries. Most es-
timates of the probabilities, WFN and WFP were signifi-
cantly different among the countries. The probabilities
and weights of harm were not significantly different bet-
ween male and female participants. There was a negative
relationship (correlation) between WFN and WFP and
years of clinical experience.y from untreated SNPTB and side effects in treated
77) Pakistan (n = 84) Bangladesh (n = 81) All countries (n = 242)
60 (30-82.5) 60 (40-70) 65 (50-75)
20 (10-30) 29.5 (20-30) 20 (8-30)
10 (5-20) 15 (10-29) 10 (5-20)
10 (4.5-20) 12.5 (5-25) 8 (5-20)
25 (10-50) 15 (10-30) 15 (10-30)
0.45) 1.5 (0.71-10) 1(0.22-4.0) 0.70 (0.23-3.1)
3.0 (1-7.4) 3 (0.57-8) 1.5 (0.6-4.6)
Table 5 Estimated weights of mortality and morbidity and values of regret in all the countries
India (n = 77) Pakistan (n = 84) Bangladesh (n = 81) All countries (n = 242)
Weight of morbidity related to the disease (%)¶ 20 (10-30) 30 (17.5-50) 35 (20-45) 25 (15-40)
Weight of morbidity related to treatment (%)¶ 80 (75-90) 50 (20-60) 50 (40-80) 60 (40-80)
Regret due to provoked but justified death (relative to
natural death)¶
1(1-2) 1 (1-2) 2 (1-2) 1 (1-2)
Regret due to provoked but unjustified death (relative
to natural death)*
3 (2.5-4) 2 (1-3) 3 (2-5) 3 (2-4)
Regret of death due to omission (relative to natural death)¶ 4 (4-5) 3 (1-3.5) 4 (3-7) 4 (3-5)
*p < 0.05, ¶ p < 0.001.
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ered that it is less harmful to commit than to omit which
is similar to the results of the study by Moreira et al.
from four LMICs [10]. Previous research has also shown
that medical decisions generally are favorable towards
treatment and the decisions depend on the perspective
of the decision maker as found in our study [11]. Young
physicians in our survey may have given a higher weight
to harm by omission considering the potential benefit of
the treatment available for PTB under DOTS strategy
adopted in most LMICs. In Moreira’s study [10], physi-
cians from Laos had given a consistently high value of
10 for WFP, but physicians in our study estimated a
lower WFP. Moreira et al. suggest that strict national
guidelines about smear positivity for initiation of anti-TB
treatment as the reason for high WFP estimated by the
Laotian physicians. Currently, the national guidelines in
most LMICs do not strictly require smear-positivity to
start anti-TB treatment; instead the guidelines provide a
separate category and treatment regimen for SNPTB.
Despite fairly accurate estimation of baseline probabil-
ities for disease morbidity and mortality by the physicians,
they are less likely to integrate them into the decision
threshold because the estimated baseline probabilities forTable 6 Weights of false negatives and false positives
India (n = 77)
Intuitive weight of false negative€ 9 (8-10)
Intuitive weight of false positive 1 (1-2)
Calculated weight of false negatives based on literature
data (without regret)
58 (56-60)
Calculated weight of false positives based on literature
data (without regret)
4.7 (4.4-5.3)
Calculated weight of false negatives based on intuitive
estimates without regret
71 (65-76)
Calculated weight of false positives based on intuitive
estimates without regret
0.7 (0.4-1.2)
Calculated weight of false negatives (WFN) (based on
intuitive estimations), regret included
302 (241.87-347.75
Calculated weight of false positives (WFP) (based on
intuitive estimations), regret included
2.02 (1.06-4.14)
€p > 0.05.treatment mortality were eightfold higher than reported in
literature data. A similar conclusion was made by Moreira
et al. since the physicians in their study also overestimated
the treatment mortality by tenfold. This was also sup-
ported by their previous study from Rwanda [5]. In the
Rwandan study the influencing factors for treatment
threshold estimated by the physicians were close to the lit-
erature data but they had wrongly integrated their estima-
tions into a final threshold for SNPTB [5].
Limitations
Our survey had some noteworthy limitations which
should be considered while interpreting the results. We
selected a convenient sample of physicians who had lim-
ited experience of caring for TB patients. The sample
was not homogenous in terms of demographics since a
higher proportion of physicians were males, particularly
in Bangladesh and the participants were relatively
young. Despite this, most probabilities and weights did
not significantly differ by gender. We did the survey
among physicians in only one location in India and
Pakistan. The participants may not be representative of
all the physicians likely to provide healthcare to TB pa-
tients in each country. Hence the results cannot bePakistan (n = 84) Bangladesh (n = 81) All countries (n = 242)
9 (5-10) 8 (7-10) 9 (7-10)
5 (2-7) 4.5 (2-6) 3 (1-6)
60 (58-64) 61 (58-63) 59 (57-62)
2.9 (1.2-3.5) 2.9 (2.4-4.7) 3.5 (2.4-4.7)
74 (48-90) 68 (56-79) 71 (57-81)
3.3 (.9-7.8) 3.9 (1.5-14) 1.7 (0.6-5.8)
) 291 (189.0-367.8) 129 (83.25-271.05) 252 (148-336)
15.64 (5.1-50.27) 5.6 (1.81-16.93) 5 (1.83-17.29)
Table 7 Ratios between weights of false negatives versus weights of false positives by four different methods¶
India (n = 77) Pakistan (n = 84) Bangladesh (n = 81) All countries (n = 242) Threshold
all countries
Intuitive WFN/Intuitive WFP 8 (4.5-9) 2 (1.4-3.3) 1.4 (0.97-2.54) 3 (1.4-5) 25 (16.7-41.7)
Calculated WFN/calculated WFP based
on literature data without regret
12 (11-13) 19 (13-26) 22 (18-52) 16 (12-26) 5.9 (3.7-7.7)_
Calculated WFN/calculated WFP based
on intuitive estimates without regret
105 (54-141) 17 (4.6-34) 21 (8-56) 33 (11-98) 2.9 (1-8.3)
Calculated WFN/calculated WFP based
on intuitive estimates with regret
131.62 (72.89-282.08) 19.04 (6.05-48.97) 28.42 (7.84-76.88) 48.69 (12.28-132.0) 2.0 (0.75-7.5)
¶Difference between ratios: p < 0.001.
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than those in which the survey was done.
The estimated probabilities and weights were for PTB,
which is a disease with a lower threshold. We used PTB
as an example to understand the role of weights and
probabilities while making medical decisions. If we had
used an example of a medical condition whose treatment
was less effective and had more serious side effects, the
physicians might have shown a higher tendency to omit
treatment. Hence our findings cannot be generalised to
all the disease conditions with varying mortality and
morbidity related to disease and treatment.
The weight of morbidity from treatment was overesti-
mated relative to the weight of the disease possibly due
to non-comprehension of the case scenario or to the in-
appropriate integration of regret in their responses.
The estimation of the regret of omission and commis-
sion was done on a scale from 1-10, with the permission
to go over the limit of 10. Other authors prefer a scale
from 1-100, with clear limits. A 1-10 scale is bound to
generate a ceiling effect [15].Figure 1 Thresholds (median and quartiles) for treatment of smear-ne
holistic: threshold calculation on the basis of regret estimations of omission
clinicians’ estimates: threshold based on clinicians’ intuitive estimates for di
Utility-based literature: threshold based on literature data for disease and tr
model: threshold based on clinicians’ intuitive estimates for disease and tre
death by omission or commission.Impact
Omission and commission biases and emotionally-driven
regret should be emphasized during decision making.
Studies about emotional factors of physicians i.e. weights
of regrets of harm due to omission or commission and the
role of estimated probabilities in medical decision making
are lacking from LMICs. Studying these factors in LMICs
where no formal training in medical decision making
exists may be useful in training of young physicians. Al-
though appropriateness of formal inclusion of emotionally
driven factors such as regret into decision making is dis-
cussed, physicians should be informed about their im-
portance. Awareness of the emotionally driven factors in
medical decision could improve the quality of decisions
and minimize the errors by omission or commission.
Future research
Future studies should estimate the baseline probabilities,
weights of regrets and treatment thresholds for other
conditions of varying morbidity and mortality from dis-
ease and treatment. Other ways of estimating thresholds,gative PTB calculated by four different approaches. Regret-based
and commission on a Likert scale (pure regret based). Utility-based
sease and treatment morbidity and mortality without clinicians’ regret.
eatment morbidity and mortality without clinicians’ regret. Hybrid
atment morbidity and mortality combined with clinicians’ regret for
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addressed also [15,17,39]. Finally, further studies should
assess the impact of training in medical decision making
on quality of medical decisions.
Conclusion
Intuitive weight of harm related to false-negatives was
estimated higher than that of false-positives. However
the mortality related to treatment was eightfold overesti-
mated. Although the observed effect of adjusting WFN
and WFP for clinician’s regret, computed in accordance
to expected utility theory, was low in this study, aware-
ness of the emotional factors should be included into
clinical decision training.
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